PDF(Pubmed)
Abstract：
Despite the elevated COVID-19 risk for older adults with cancer, vaccine hesitancy poses a significant barrier to their immunization. Intriguingly, there is limited research on the prevalence of willingness to receive the second booster dose and associated determinants in older adults with cancer.
Our objective was to ascertain the level of awareness about COVID-19 vaccines and to uncover the factors influencing the willingness to receive the second booster among Chinese cancer patients aged 65 years and over.
To achieve our objective, we conducted a multicenter cross-sectional study in four tertiary hospitals from four provinces of China. This involved using a Health Belief Model (HBM) based self-administered questionnaire and medical records. Subsequently, we employed multivariable logistic regression to identify factors influencing the second COVID-19 booster vaccine willingness.
Our results showed that among 893 eligible participants, 279 (31.24%) were aged 65 years and over, and 614 (68.76%) were younger. Interestingly, the willingness to receive the second COVID-19 booster vaccine was 34.1% (95/279) (OR: 1.043, 95% CI: 0.858, 1.267) in participants aged 65 years and over, which was similar to participants aged under 65 years (34.1% vs. 35.5%, p = 0.673). Furthermore, our findings revealed that a positive attitude toward the booster and recommendations from healthcare providers and family members were positively associated with vaccine willingness. Conversely, perceptions of negative impacts on cancer control and vaccine accessibility regarding the second COVID-19 booster were inversely related to the outcome event (all p < 0.05).
Our study concludes with the finding of a low willingness toward the second COVID-19 booster in Chinese cancer patients, particularly in the older adults, a fact which warrants attention. This reluctance raises their risk of infection and potential for severe outcomes. Consequently, we recommend using media and community outreach to dispel misconceptions, promote the booster\'s benefits, and encourage vaccine discussions with healthcare providers and family members.
Our objective was to ascertain the level of awareness about COVID-19 vaccines and to uncover the factors influencing the willingness to receive the second booster among Chinese cancer patients aged 65 years and over.
To achieve our objective, we conducted a multicenter cross-sectional study in four tertiary hospitals from four provinces of China. This involved using a Health Belief Model (HBM) based self-administered questionnaire and medical records. Subsequently, we employed multivariable logistic regression to identify factors influencing the second COVID-19 booster vaccine willingness.
Our results showed that among 893 eligible participants, 279 (31.24%) were aged 65 years and over, and 614 (68.76%) were younger. Interestingly, the willingness to receive the second COVID-19 booster vaccine was 34.1% (95/279) (OR: 1.043, 95% CI: 0.858, 1.267) in participants aged 65 years and over, which was similar to participants aged under 65 years (34.1% vs. 35.5%, p = 0.673). Furthermore, our findings revealed that a positive attitude toward the booster and recommendations from healthcare providers and family members were positively associated with vaccine willingness. Conversely, perceptions of negative impacts on cancer control and vaccine accessibility regarding the second COVID-19 booster were inversely related to the outcome event (all p < 0.05).
Our study concludes with the finding of a low willingness toward the second COVID-19 booster in Chinese cancer patients, particularly in the older adults, a fact which warrants attention. This reluctance raises their risk of infection and potential for severe outcomes. Consequently, we recommend using media and community outreach to dispel misconceptions, promote the booster\'s benefits, and encourage vaccine discussions with healthcare providers and family members.
摘要：
■尽管患有癌症的老年人患COVID-19的风险升高，疫苗的犹豫对他们的免疫接种构成了重大障碍。有趣的是，关于老年癌症患者接受第二加强剂量的意愿的患病率和相关决定因素的研究有限.
■我们的目标是确定对COVID-19疫苗的认知水平，并揭示影响65岁及以上中国癌症患者接受第二次加强疫苗接种意愿的因素。
■为了实现我们的目标，我们在中国4个省的4家三级医院进行了一项多中心横断面研究.这涉及使用基于健康信念模型（HBM）的自我管理问卷和医疗记录。随后，我们采用多变量逻辑回归来确定影响第二次COVID-19加强疫苗接种意愿的因素.
■我们的结果显示，在893名符合条件的参与者中，279人(31.24%)年龄在65岁及以上，和614（68.76％）年轻。有趣的是,在65岁及以上的参与者中，接受第二种COVID-19加强疫苗的意愿为34.1％（95/279）（OR：1.043，95％CI：0.858，1.267），这与65岁以下的参与者相似(34.1%vs.35.5%,p=0.673)。此外，我们的研究结果显示,对加强疫苗接种的积极态度以及医疗保健提供者和家庭成员的建议与疫苗接种意愿呈正相关.相反，关于第二次COVID-19加强剂对癌症控制和疫苗可及性的负面影响的看法与结局事件呈负相关(均p<0.05).
我们的研究结论是，中国癌症患者对第二种COVID-19加强剂的意愿很低，特别是在老年人中，一个值得关注的事实。这种不情愿增加了他们感染的风险和严重结局的可能性。因此,我们建议使用媒体和社区外展来消除误解，促进助推器的好处，并鼓励与医疗保健提供者和家庭成员讨论疫苗。
■我们的目标是确定对COVID-19疫苗的认知水平，并揭示影响65岁及以上中国癌症患者接受第二次加强疫苗接种意愿的因素。
■为了实现我们的目标，我们在中国4个省的4家三级医院进行了一项多中心横断面研究.这涉及使用基于健康信念模型（HBM）的自我管理问卷和医疗记录。随后，我们采用多变量逻辑回归来确定影响第二次COVID-19加强疫苗接种意愿的因素.
■我们的结果显示，在893名符合条件的参与者中，279人(31.24%)年龄在65岁及以上，和614（68.76％）年轻。有趣的是,在65岁及以上的参与者中，接受第二种COVID-19加强疫苗的意愿为34.1％（95/279）（OR：1.043，95％CI：0.858，1.267），这与65岁以下的参与者相似(34.1%vs.35.5%,p=0.673)。此外，我们的研究结果显示,对加强疫苗接种的积极态度以及医疗保健提供者和家庭成员的建议与疫苗接种意愿呈正相关.相反，关于第二次COVID-19加强剂对癌症控制和疫苗可及性的负面影响的看法与结局事件呈负相关(均p<0.05).
我们的研究结论是，中国癌症患者对第二种COVID-19加强剂的意愿很低，特别是在老年人中，一个值得关注的事实。这种不情愿增加了他们感染的风险和严重结局的可能性。因此,我们建议使用媒体和社区外展来消除误解，促进助推器的好处，并鼓励与医疗保健提供者和家庭成员讨论疫苗。
